Rubius Therapeutics (DB:5RT) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

5RT Overzicht aandelen

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. Meer informatie

5RT fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( €2M )

Aandelen zijn zeer illiquide

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst is de afgelopen 5 jaar met 21.3% per jaar gedaald

+ 1 meer risico

Rubius Therapeutics, Inc. Concurrenten

Epigenomics

XTRA:ECX

€616.0k

bioXXmed

XTRA:T5O

€1.4m

co.don

XTRA:CNW

€6.5m

Deutsche Biotech Innovativ

DUSE:DBI

€1.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Rubius Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$0.013
52 Week Hoogtepunt	US$1.40
52 Week Laag	US$0.013
Bèta	2.39
11 maand verandering	0%
3 maanden verandering	-23.53%
1 Jaar Verandering	n/a
33 jaar verandering	-99.75%
5 jaar verandering	n/a
Verandering sinds IPO	-99.94%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	5RT	DE Biotechs	DE Markt
7D	0%	-0.7%	-0.02%
1Y	n/a	-17.2%	8.2%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 5RT presteerde ten opzichte van de German Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 5RT presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is 5RT's price volatile compared to industry and market?
5RT volatility
5RT Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 5RT is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 5RT in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	6	Craig Jalbert	www.rubiustx.com

Rubius Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Rubius Therapeutics zich tot de beurswaarde?
5RT fundamentele statistieken
Marktkapitalisatie	€1.73m
Inkomsten(TTM)	-€167.23m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is 5RT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
5RT resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$179.67m
Inkomsten	-US$179.67m

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.99
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 5RT op de lange termijn?

Bekijk historische prestaties en vergelijking

This company listing is no longer active

5RT Overzicht aandelen

Risicoanalyse

Rubius Therapeutics, Inc. Concurrenten

XTRA:ECX

€616.0k

XTRA:T5O

€1.4m

XTRA:CNW

€6.5m

DUSE:DBI

€1.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Less than half of directors are independent

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Recent updates

Less than half of directors are independent

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

Rubius Therapeutics, Inc. Appoints Susanne Schaffert to Its Board of Directors

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 2000 Growth Index

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics, Inc. Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Rubius Therapeutics, Inc., Annual General Meeting, May 12, 2022

Rubius Therapeutics, Inc. to Report Q4, 2021 Results on Feb 25, 2022

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Rubius Therapeutics to Highlight the Power of RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 3000E Value Index

Rubius Therapeutics, Inc. Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® in Ongoing Phase 1/2 Clinical Trial for Treatment of Advanced Solid Tumors

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Rubius Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

Rubius Therapeutics Announces Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240

New 90-day high: €12.50

Rubius Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €8.10

Rubius Therapeutics, Inc. Provides an Operational Update

New 90-day high: €7.90

New 90-day high: €4.92

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic Clinical Oncology Program, Rtx-240, at the Society for Immunotherapy of Cancer’s Annual Meeting

Rubius Therapeutics, Inc. Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240

Rubius Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low: €3.84

Rubius Therapeutics, Inc. Appoints Jose Carmona as Principal Financial Officer, Principal Accounting Officer and Treasurer Effective as of October 1, 2020

New 90-day low: €3.92

New 90-day low - €4.00

Rubius Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

New 90-day low - €4.92

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Rubius Therapeutics, Inc. Samenvatting

0.0x

0.0x

Inkomsten en omzet